vs
香颂国际控股（CHSN）与Protalix BioTherapeutics, Inc.（PLX）财务数据对比。点击上方公司名可切换其他公司
Protalix BioTherapeutics, Inc.的季度营收约是香颂国际控股的1.0倍（$9.1M vs $8.7M），香颂国际控股净利率更高（-12.1% vs -60.3%，领先48.3%），香颂国际控股同比增速更快（15.2% vs -49.9%）
香颂国际控股是一家主营高端烘焙连锁业务的食品企业，核心市场位于中国内地，产品线涵盖新鲜面包、手工糕点、定制庆典蛋糕、特色饮品，同时向合作零售网点供应冷冻烘焙产品，服务追求高品质饮食的中等收入消费群体。
Protalix BioTherapeutics是一家以色列制药企业，核心产品为植物源酶制剂他利苷酶阿尔法，该产品已获美国食品药品监督管理局批准，用于治疗戈谢病，专注于开发创新生物技术药物服务患者需求。
CHSN vs PLX — 直观对比
营收规模更大
PLX
是对方的1.0倍
$8.7M
营收增速更快
CHSN
高出65.1%
-49.9%
净利率更高
CHSN
高出48.3%
-60.3%
损益表 — Q2 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $8.7M | $9.1M |
| 净利润 | $-1.0M | $-5.5M |
| 毛利率 | 44.5% | 49.4% |
| 营业利润率 | -13.7% | -51.1% |
| 净利率 | -12.1% | -60.3% |
| 营收同比 | 15.2% | -49.9% |
| 净利润同比 | -4579.7% | -184.8% |
| 每股收益（稀释后） | $-2.87 | $-0.06 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CHSNPLX
| Q4 25 | — | $9.1M | ||
| Q3 25 | — | $17.9M | ||
| Q2 25 | $8.7M | $15.7M | ||
| Q1 25 | — | $10.1M | ||
| Q4 24 | — | $18.2M | ||
| Q3 24 | — | $18.0M | ||
| Q2 24 | $7.5M | $13.5M | ||
| Q4 23 | — | $10.5M |
净利润CHSNPLX
| Q4 25 | — | $-5.5M | ||
| Q3 25 | — | $2.4M | ||
| Q2 25 | $-1.0M | $164.0K | ||
| Q1 25 | — | $-3.6M | ||
| Q4 24 | — | $6.5M | ||
| Q3 24 | — | $3.2M | ||
| Q2 24 | $23.4K | $-2.2M | ||
| Q4 23 | — | $-6.0M |
毛利率CHSNPLX
| Q4 25 | — | 49.4% | ||
| Q3 25 | — | 53.4% | ||
| Q2 25 | 44.5% | 62.5% | ||
| Q1 25 | — | 19.1% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 53.4% | ||
| Q2 24 | 41.5% | 29.8% | ||
| Q4 23 | — | 15.5% |
营业利润率CHSNPLX
| Q4 25 | — | -51.1% | ||
| Q3 25 | — | 11.9% | ||
| Q2 25 | -13.7% | 7.5% | ||
| Q1 25 | — | -41.0% | ||
| Q4 24 | — | 39.6% | ||
| Q3 24 | — | 22.2% | ||
| Q2 24 | -7.4% | -18.0% | ||
| Q4 23 | — | -53.5% |
净利率CHSNPLX
| Q4 25 | — | -60.3% | ||
| Q3 25 | — | 13.2% | ||
| Q2 25 | -12.1% | 1.0% | ||
| Q1 25 | — | -35.8% | ||
| Q4 24 | — | 35.6% | ||
| Q3 24 | — | 18.0% | ||
| Q2 24 | 0.3% | -16.4% | ||
| Q4 23 | — | -57.6% |
每股收益（稀释后）CHSNPLX
| Q4 25 | — | $-0.06 | ||
| Q3 25 | — | $0.03 | ||
| Q2 25 | $-2.87 | $0.00 | ||
| Q1 25 | — | $-0.05 | ||
| Q4 24 | — | $0.10 | ||
| Q3 24 | — | $0.03 | ||
| Q2 24 | $0.15 | $-0.03 | ||
| Q4 23 | — | $-0.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $22.1M | $14.7M |
| 总债务越低越好 | $4.5M | — |
| 股东权益账面价值 | $24.5M | $48.2M |
| 总资产 | $51.6M | $82.3M |
| 负债/权益比越低杠杆越低 | 0.18× | — |
8季度趋势，按日历期对齐
现金及短期投资CHSNPLX
| Q4 25 | — | $14.7M | ||
| Q3 25 | — | $13.6M | ||
| Q2 25 | $22.1M | $17.9M | ||
| Q1 25 | — | $19.5M | ||
| Q4 24 | — | $19.8M | ||
| Q3 24 | — | $27.4M | ||
| Q2 24 | $4.1M | $23.4M | ||
| Q4 23 | — | $23.6M |
总债务CHSNPLX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $4.5M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q4 23 | — | — |
股东权益CHSNPLX
| Q4 25 | — | $48.2M | ||
| Q3 25 | — | $52.9M | ||
| Q2 25 | $24.5M | $49.9M | ||
| Q1 25 | — | $45.2M | ||
| Q4 24 | — | $43.2M | ||
| Q3 24 | — | $32.4M | ||
| Q2 24 | $12.1M | $28.6M | ||
| Q4 23 | — | $33.6M |
总资产CHSNPLX
| Q4 25 | — | $82.3M | ||
| Q3 25 | — | $82.3M | ||
| Q2 25 | $51.6M | $78.5M | ||
| Q1 25 | — | $73.9M | ||
| Q4 24 | — | $73.4M | ||
| Q3 24 | — | $61.6M | ||
| Q2 24 | $38.7M | $91.5M | ||
| Q4 23 | — | $84.4M |
负债/权益比CHSNPLX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.18× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q4 23 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-390.3K | $2.0M |
| 自由现金流经营现金流 - 资本支出 | — | $1.6M |
| 自由现金流率自由现金流/营收 | — | 17.8% |
| 资本支出强度资本支出/营收 | — | 4.4% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-13.6M |
8季度趋势，按日历期对齐
经营现金流CHSNPLX
| Q4 25 | — | $2.0M | ||
| Q3 25 | — | $-3.7M | ||
| Q2 25 | $-390.3K | $-5.2M | ||
| Q1 25 | — | $-5.1M | ||
| Q4 24 | — | $4.0M | ||
| Q3 24 | — | $4.1M | ||
| Q2 24 | $806.1K | $-3.6M | ||
| Q4 23 | — | $3.6M |
自由现金流CHSNPLX
| Q4 25 | — | $1.6M | ||
| Q3 25 | — | $-4.2M | ||
| Q2 25 | — | $-5.7M | ||
| Q1 25 | — | $-5.4M | ||
| Q4 24 | — | $3.6M | ||
| Q3 24 | — | $4.0M | ||
| Q2 24 | $771.9K | $-3.8M | ||
| Q4 23 | — | $3.3M |
自由现金流率CHSNPLX
| Q4 25 | — | 17.8% | ||
| Q3 25 | — | -23.7% | ||
| Q2 25 | — | -36.2% | ||
| Q1 25 | — | -53.0% | ||
| Q4 24 | — | 19.6% | ||
| Q3 24 | — | 22.4% | ||
| Q2 24 | 10.2% | -28.1% | ||
| Q4 23 | — | 31.9% |
资本支出强度CHSNPLX
| Q4 25 | — | 4.4% | ||
| Q3 25 | — | 2.8% | ||
| Q2 25 | — | 2.8% | ||
| Q1 25 | — | 3.0% | ||
| Q4 24 | — | 2.3% | ||
| Q3 24 | — | 0.5% | ||
| Q2 24 | 0.5% | 1.3% | ||
| Q4 23 | — | 2.4% |
现金转化率CHSNPLX
| Q4 25 | — | — | ||
| Q3 25 | — | -1.58× | ||
| Q2 25 | — | -31.91× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.61× | ||
| Q3 24 | — | 1.27× | ||
| Q2 24 | 34.43× | — | ||
| Q4 23 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CHSN
暂无分部数据
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
